Stocks ticked higher this morning, and seemed to be looking for a continuation of yesterday’s strength. Yesterday’s gains pushed the S&P 500 back into positive territory for the month and helped put a dent in the Nasdaq’s monthly decline.
Growth stocks, including technology, seem to be regaining leadership as yield and inflation fears ease. Airlines and other reopening stocks were also in the spotlight again this morning. Our trade alert for today highlights a growth story that also stands to benefit as the reopening steams ahead.
TRUE MARKET INSIDERS:
Warning: Move Your Money ASAP
The clock just started on the biggest stock market event in twenty years. And the next couple months could determine who will become extremely wealthy in 2022 – and who won’t. [Full Story…]
Health Catalyst (HCAT) is a software-as-a-service company that provides a cloud-based data platform, analytics software and professional services for hospitals and other healthcare organizations.
The pandemic induced shutdown of March 2020 sent HCAT plunging to an all time low of $23.39. But it actually created an excellent buying opportunity as the stock has more than doubled since – and the Wall Street pros covering the stock say this strength will likely continue.
HCAT is gaining favor within the analyst community. The stock garners a consensus Strong Buy recommendation from the 14 analysts covering it along with a consensus price target of $58.29. Earlier this month, J.P. Morgan initiated coverage with a Buy rating on the stock and a $63 price target.
At Raymond James, five-star analyst John Ransom reiterated his Strong Buy recommendation, citing that he expects business to accelerate in the coming months as the COVID-19 crisis gradually abates.
“Post-pandemic we expect to see increased demand for Health Catalyst suite of solutions and note that the discounts provided to customers in the depths of the pandemic should buy a significant amount of goodwill and is evidence of the company’s dedication to helping providers improve,” writes Ransom, who specializes in the Healthcare sector.
Stifel analyst David Grossman sums up the reason for their Buy rating, “Our thesis reflects HCAT’s market leadership in the Healthcare Analytics market. We expect HCAT to maintain 20%-plus organic growth through a combination of new clients and contractual price escalators.”
Health Catalyst shares have added about 22% since the beginning of the year versus the S&P 500’s gain of 13% and there may be plenty of runway ahead.
Where to invest $1,000 right now...
Before you consider buying Health Catalyst, you'll want to see this.
Investing legend, Keith Kohl just revealed his #1 stock for 2022...
And it's not Health Catalyst.
Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on this tiny company that trades publicly for $5.
Keith say’s he thinks investors will be able to turn a small $50 stake into $150,000.
Find that to be extraordinary?
But you have to act now, because a catalyst coming in a few weeks is set to take this company mainstream... And by then, it could be too late.
Jeff Bezos Just Poured $10 Billion Into This…
Not many people know this story… But in 1998, Bezos invested $250,000 of his own money in Google, when the company was just getting started out of a garage in California. When Google went public in 2004, that $250,000 investment translated into 3.3 million shares of Google stock. Nobody knows if Bezos has sold any shares. If he hasn’t, today they’re worth more than $5.6 billion.Jeff Bezos is betting big on a new trend. This time he’s planning to invest $10 billion of his own money in this exciting new trend. That’s 40,000 times more money than what he invested in Google. That’s how big he thinks this could be. [Full Story…]